We are live on ! Find out more
CUAMC

China Universal Asset Management Company Portfolio holdings

AUM $1.67B
1-Year Est. Return 89%
This Fund
S&P 500
This Quarter Est. Return
+17.99%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$12.1M
Cap. Flow
-$142M
Cap. Flow %
-13.41%
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
262
Reduced
172
Closed
24

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$6.54M
2
IAUM icon
iShares Gold Trust Micro
IAUM
+$4.59M
3
GLDM icon
SPDR Gold MiniShares Trust
GLDM
+$3.58M
4
INTU icon
Intuit
INTU
+$3.2M
5
TMUS icon
T-Mobile US
TMUS
+$2.41M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$17.2M
2
MSFT icon
Microsoft
MSFT
+$10M
3
NVDA icon
NVIDIA
NVDA
+$9.7M
4
AMZN icon
Amazon
AMZN
+$7.99M
5
AVGO icon
Broadcom
AVGO
+$6.64M

Sector Composition

Rank Sector Weight
1 Technology 38.15%
2 Healthcare 22.68%
3 Communication Services 12.64%
4 Consumer Discretionary 11.62%
5 Consumer Staples 3.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
426
State Street SPDR S&P Biotech ETF
XBI
$10.5B
$42.1K ﹤0.01%
508
-7,514
-94% -$599K
INBX icon
427
Inhibrx
INBX
$1.44B
$41.5K ﹤0.01%
2,907
+3
+0.1% +$39
YMAB
428
DELISTED
Y-mAbs Therapeutics
YMAB
$41K ﹤0.01%
9,097
+113
+1% +$508
ACIU icon
429
AC Immune
ACIU
$267M
$40.9K ﹤0.01%
20,167
+330
+2% +$574
CDXS icon
430
Codexis
CDXS
$172M
$40.6K ﹤0.01%
16,639
+23
+0.1% +$54
SCPH
431
DELISTED
scPharmaceuticals
SCPH
$40.4K ﹤0.01%
10,603
+566
+6% +$1.76K
ESPR
432
DELISTED
Esperion Therapeutics
ESPR
$39.2K ﹤0.01%
39,808
+286
+0.7% +$286
DSGN icon
433
Design Therapeutics
DSGN
$917M
$38.4K ﹤0.01%
11,402
+45
+0.4% +$168
CRGX
434
DELISTED
CARGO Therapeutics
CRGX
$38.2K ﹤0.01%
9,262
+30
+0.3% +$128
LRMR icon
435
Larimar Therapeutics
LRMR
$454M
$37.2K ﹤0.01%
12,860
+61
+0.5% +$141
EDIT icon
436
Editas Medicine
EDIT
$436M
$37K ﹤0.01%
16,813
+255
+2% +$417
OMER icon
437
Omeros
OMER
$992M
$35.3K ﹤0.01%
11,768
+144
+1% +$717
VYGR icon
438
Voyager Therapeutics
VYGR
$197M
$34.6K ﹤0.01%
11,114
+157
+1% +$506
FDMT icon
439
4D Molecular Therapeutics
FDMT
$621M
$34.5K ﹤0.01%
9,304
+17
+0.2% +$60
ENTA icon
440
Enanta Pharmaceuticals
ENTA
$393M
$32.5K ﹤0.01%
4,293
+14
+0.3% +$84
ALEC icon
441
Alector
ALEC
$240M
$28.1K ﹤0.01%
20,083
+208
+1% +$260
LXEO icon
442
Lexeo Therapeutics
LXEO
$382M
$26.8K ﹤0.01%
6,667
+35
+0.5% +$115
KYTX icon
443
Kyverna Therapeutics
KYTX
$489M
$26.6K ﹤0.01%
8,680
+21
+0.2% +$52
VGT icon
444
Vanguard Information Technology ETF
VGT
$149B
$26.5K ﹤0.01%
320
+168
+111% +$12.2K
LYEL icon
445
Lyell Immunopharma
LYEL
$347M
$26.2K ﹤0.01%
2,966
+36
+1% +$328
FATE icon
446
Fate Therapeutics
FATE
$317M
$25.8K ﹤0.01%
23,024
+179
+0.8% +$208
ALGN icon
447
Align Technology
ALGN
$12.4B
$25.2K ﹤0.01%
133
– –
NMRA icon
448
Neumora Therapeutics
NMRA
$317M
$23.8K ﹤0.01%
32,486
+80
+0.2% +$61
NKTX icon
449
Nkarta
NKTX
$171M
$23.7K ﹤0.01%
14,252
+97
+0.7% +$178
IRWD icon
450
Ironwood Pharmaceuticals
IRWD
$714M
$23.3K ﹤0.01%
32,501
+402
+1% +$316
16 17
18
19 20

Similar funds

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
JPM
JANA Partners Management New York $1.67B AUM 1.66% 1-Year Est. Return
CPO
Cerity Partners OCIO New York $1.67B AUM 13.22% 1-Year Est. Return
LCI
L1 Capital International Sydney NSW 2000, Australia $1.68B AUM 9.83% 1-Year Est. Return
GWM
GDS Wealth Management Flower Mound, Texas $1.66B AUM 18.11% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

China Universal Asset Management Company's Q2 2025 Portfolio in Review

As of Q2 2025, China Universal Asset Management Company held 501 positions worth $1.06B, down 1.1% from $1.07B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

China Universal Asset Management Company withdrew a net $142M in Q2 2025, closing 24 positions and reducing 172 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $2.81M position sold in full.

By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 37% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, China Universal Asset Management Company opened a new position in Tencent Music worth $1.66M.

  • China Universal Asset Management Company's largest Q2 2025 buy was Tencent Music: 85,000 shares worth $1.66M.
  • China Universal Asset Management Company added most to SPDR Gold Trust in Q2 2025, an estimated $6.54M increase.
  • China Universal Asset Management Company's biggest Q2 2025 reduction was Apple, cutting an estimated $17.2M.
  • China Universal Asset Management Company fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $2.81M.
  • China Universal Asset Management Company's ten largest holdings make up 38% of its $1.06B portfolio in Q2 2025.
  • China Universal Asset Management Company opened 15 new positions and closed 24 in Q2 2025.
  • China Universal Asset Management Company's portfolio value fell 1.1% quarter-over-quarter to $1.06B.

Based on China Universal Asset Management Company's 13F filing for Q2 2025, filed 28 Aug 2025.